Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
Sorafenib is a multikinase inhibitor used as a second-line treatment for metastatic renal cell carcinoma (mRCC). However, it is very difficult to estimate sorafenib dosage because it is difficult to maintain stable administration and dosage intervals due to several side-effects. We examined the correlation between relative dose intensity (RDI) and clinical outcome of sorafenib therapy in a multi-institutional study.
A study population of 70 first-line therapy-refractory patients with pathologically confirmed RCC was eligible for this investigation. Clinical outcomes were evaluated according to clinicopathological features and RDI for 1month (1M-RDI).
There was significant difference in progression-free survival (PFS) time but not overall survival (OS) time when the 1M-RDI cut-off value was ⩾50%. In 15 patients (21.4%) with 1M-RDI of < 50%, median PFS time was 4.1months (95% I collagen (95% CI): 2.0-6.2), whereas it was 10.5months (95% CI: 7.6-13.4) in the patients with 1M-RDI of ⩾50% (P=0.022). Multivariate analysis showed 1M-RDI status to be significantly associated with PFS (HR: 3.838, 95% CI: 1.658-8.883, P=0.002) but not OS (P=0.328).
Although this study was retrospective, a 1M-RDI cut-off value of ⩾50% for sorafenib may be the first factor to predict PFS but not OS in cytokine pretreated mRCC patients. The data indicate that a dose of 400mg/day of sorafenib administered successively for the first one month was necessary to prolong disease stabilisation and could be tolerated by Japanese patients.
Written by:
Kawashima A, Takayama H, Arai Y, Tanigawa G, Nin M, Kajikawa J, Imazu T, Kinoshita T, Yasunaga Y, Inoue H, Nishimura K, Takada S, Nishimura K, Tsujimura A, Nonomura N. Are you the author?
Reference: Eur J Cancer. 2011 May 6. Epub ahead of print.
doi: 10.1016/j.ejca.2011.04.001
PubMed Abstract
PMID: 21550799
UroToday.com Renal Cancer Section
